Q1 FY27 results: PAT up 38%, EBITDA margin expands to 10%

Pat Growth 25pctEbitda Margin ExpansionResults View source PDF Explain this filing

ANUHPHR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.9%Reaction day

₹79.88

prior close

₹79.99

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-2.8% vs market

Pharmaceuticals peers, median of 165sector-0.1%-2.8% vs sector

On the reaction day the stock moved 2.8 pts less than Nifty Microcap 250 and 2.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.2

10m

-1.4

15m

-1.6

30m

-2.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.9-0.1-2.8-0.1-2.8

Next day

-2.7-0.2-2.5+0.0-2.8

-3.4+0.1-3.6-0.0-3.4

-3.9+0.3-4.2+0.3-4.2

-4.7+0.4-5.1-0.5-4.2

-5.2+0.5-5.7-1.1-4.1

-4.9+0.3-5.1-1.8-3.0

15d

+2.3+1.9+0.5+0.1+2.2

+14.8+2.2+12.6+1.4+13.4

+1.3-1.2+2.5-2.0+3.4

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Anuh Pharma Q1 FY27 (quarter ended 30 June 2026): Revenue from operations at Rs 19,381 lakhs versus Rs 18,648 lakhs in Q1 FY26. Profit after tax rose 38% to Rs 1,142 lakhs. EBITDA grew to Rs 1,936 lakhs; margin expanded to 9.99% from 7.34%. Board also noted withdrawal of reclassification requests by 3 promoter group members (0.83% combined holding) and adopted revised related party transaction policy.

Likely market impact

Strong quarterly earnings on margin expansion; promoter group structure unchanged, no float impact.